Sugi Predict

Sugi Predict / Targets / CARM1

CARM1

Histone-arginine methyltransferase CARM1 · Q86X55 · CARM1 on Sugi Atlas →

43,951 patent compounds predicted against CARM1, 22,817 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL768609 SCHEMBL768609 0.52 18/20
SCHEMBL39876 SCHEMBL39876 0.58 16/20
SCHEMBL768608 SCHEMBL768608 0.53 16/20
SCHEMBL39855 SCHEMBL39855 0.54 12/20
SCHEMBL488349 SCHEMBL488349 0.59 11/20
SCHEMBL304608 SCHEMBL304608 0.51 10/20
SCHEMBL792157 SCHEMBL792157 0.68 9/20
SCHEMBL304374 SCHEMBL304374 0.50 9/20
SCHEMBL381729 SCHEMBL381729 0.64 8/20
Lithium Ion Lithium Ion (SCHEMBL381730) 0.63 8/20
SCHEMBL681608 SCHEMBL681608 0.62 7/20
SCHEMBL303681 SCHEMBL303681 0.50 7/20
SCHEMBL304344 SCHEMBL304344 0.50 7/20
SCHEMBL77007 SCHEMBL77007 0.95 6/20
SCHEMBL606815 SCHEMBL606815 0.52 6/20
SCHEMBL604129 SCHEMBL604129 0.43 6/20
Ademetionine Ademetionine (SCHEMBL25176) 1.00 5/20
Ademetionine Ademetionine (SCHEMBL25177) 1.00 5/20
Ademetionine Ademetionine (SCHEMBL55479) 1.00 5/20
Ademetionine Ademetionine (SCHEMBL59293) 1.00 5/20

Clinical trials — most relevant to CARM1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Mechanisms of Immune Deficiency nanUNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1) nanRECRUITING
DNA Methylation and Perioperative Pain Treatment nanCOMPLETED
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders nanNOT_YET_RECRUITING
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC. nanUNKNOWN
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CARM1 binder may also engage these)

ProteinNameSimilarity
Q6DC04 — 1.000 Q6DC04 →
Q5XK84 — 1.000 Q5XK84 →
Q9WVG6 — 1.000 Q9WVG6 →
Q4AE70 — 1.000 Q4AE70 →
Q7Q2B7 — 0.986 Q7Q2B7 →
B3M1E1 — 0.985 B3M1E1 →
B3P4N5 — 0.985 B3P4N5 →
B0W3L6 — 0.984 B0W3L6 →
B4JXV2 — 0.984 B4JXV2 →
B4KA23 — 0.983 B4KA23 →
B4GZ20 — 0.982 B4GZ20 →
Q29B63 — 0.982 Q29B63 →
B4LVS8 — 0.981 B4LVS8 →
Q9VH48 — 0.981 Q9VH48 →
B4PVH6 — 0.981 B4PVH6 →
P31266 — 0.981 P31266 →
B4HJC0 — 0.981 B4HJC0 →
Q921C3 — 0.981 Q921C3 →
B4NKI9 — 0.980 B4NKI9 →
Q5RGQ2 — 0.979 Q5RGQ2 →
B4QVW6 — 0.979 B4QVW6 →
E9PUQ8 — 0.979 E9PUQ8 →
Q9H694 — 0.979 Q9H694 →
Q174R2 — 0.979 Q174R2 →
Q5U4T7 — 0.979 Q5U4T7 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.979 landscape →
Q6DD21 — 0.978 Q6DD21 →
Q99P88 — 0.978 Q99P88 →
B5DDX6 — 0.978 B5DDX6 →
Q6DEZ2 — 0.978 Q6DEZ2 →